2022-11-16 · Class I · Terminated
D-0058-2023 · Viatris Inc
Octreotide · Presence of Particulate Matter: Product complaint for the presence of glass particles in a syringe.
Open attributed report →FDA enforcement report year
2022 FDA peptide enforcement reports
2 dated reports mapped only through exact reviewed application-number annotations.
2022-05-25 · Class II · Completed
D-0884-2022 · Cardinal Health Inc.
Dulaglutide · TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions
Open attributed report →